[HTML][HTML] Erlotinib in lung cancer—molecular and clinical predictors of outcome
… benefit from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer,
we … of EGFR, and mutation status of the gene in a subgroup of patients in the BR.21 study. …
we … of EGFR, and mutation status of the gene in a subgroup of patients in the BR.21 study. …
[HTML][HTML] Erlotinib in previously treated non–small-cell lung cancer
FA Shepherd, J Rodrigues Pereira… - New England journal …, 2005 - Mass Medical Soc
… to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs
survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. …
survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. …
Erlotinib: a new therapeutic approach for non-small cell lung cancer
P Bonomi - Expert opinion on investigational drugs, 2003 - Taylor & Francis
… patients with EGFR-negative tumours. In contrast, increasing severity of rash in erlotinib-treated
lung cancer patients was … cancer and head and neck cancer patients [44]. The median …
lung cancer patients was … cancer and head and neck cancer patients [44]. The median …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …
Retrospective study of erlotinib in patients with advanced squamous lung cancer
JS Tseng, TY Yang, KC Chen, KH Hsu, HY Chen… - Lung Cancer, 2012 - Elsevier
… low in lung SCC. The aim of this study was to evaluate the status … erlotinib treatment and
EGFR mutation in lung SCC patients. Methods: We retrospectively enrolled lung cancer patients …
EGFR mutation in lung SCC patients. Methods: We retrospectively enrolled lung cancer patients …
Erlotinib in patients with advanced lung squamous cell carcinoma
CL Chiang, CM Tsai, TY Chou, YM Chen… - Cancer chemotherapy …, 2013 - Springer
… patients with advanced LSQC treated with erlotinib monotherapy during January 2006 to
October 2011. We included lung cancer patients … , had history of erlotinib treatment, and had …
October 2011. We included lung cancer patients … , had history of erlotinib treatment, and had …
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer
JF Lu, SM Eppler, J Wolf, M Hamilton… - Clinical …, 2006 - Wiley Online Library
… Our objective was to assess the pharmacokinetics of erlotinib in a large patient population
with … and diarrhea) in patients with non-small cell lung cancer receiving single-agent erlotinib. …
with … and diarrhea) in patients with non-small cell lung cancer receiving single-agent erlotinib. …
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
… or placebo with gemcitabine and carboplatin or cisplatin followed by maintained erlotinib
or placebo in patients with stage IIIB/IV non-small-cell lung cancer. The study was undertaken …
or placebo in patients with stage IIIB/IV non-small-cell lung cancer. The study was undertaken …
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Purpose Several cases have been reported in which central nervous system (CNS) metastases
of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. …
of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. …
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non–small-cell lung cancer: a phase III trial
GV Scagliotti, M Krzakowski, A Szczesna… - Journal of clinical …, 2012 - ascopubs.org
… erlotinib may enhance antitumor activity compared with either agent alone in non–small-cell
lung cancer (… plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. …
lung cancer (… plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. …
相关搜索
- standard chemotherapy in patients lung cancer
- clinically selected patients lung cancer
- egfr mutations in patients lung cancer
- cerebrospinal fluid of patients lung cancer
- cell lung cancer
- patients with lung adenocarcinoma
- erlotinib maintenance therapy lung cancer
- first line erlotinib lung cancer
- phase ii trial lung cancer
- trial of erlotinib lung cancer
- non-small cell lung cancer treatment
- small cell lung cancer randomized phase
- second line treatment lung cancer
- small cell lung cancer sequential erlotinib
- small cell lung cancer erlotinib hydrochloride
- small cell lung cancer erlotinib alone